Recruiting

Observational Study

Sponsor:

The Cleveland Clinic

Code:

NCT03121404

Conditions

Cirrhosis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Accepted

Interventions

Rectus abdominis muscle biopsy

Study Details

Brief summary:

Cirrhosis is characterized by loss of muscle as well as fat mass, which increases morbidity and mortality before, during, and after liver transplantation. A common mechanism for the reduced muscle and fat mass in cirrhosis is an increased expression of the TGF (transforming growth factor)beta superfamily member, myostatin, in the muscle and adipose tissue. The present study will examine the expression of myostatin, its receptor and intracellular signaling pathways in the skeletal muscle and mesenteric adipose tissue in cirrhotic patients undergoing liver transplantation as compared to healthy controls undergoing planned abdominal surgery. 16 cirrhotic patients will be identified from the transplant list, and 16 healthy controls from outpatient surgery lists. Nutritional assessment will be performed, including anthropometry (triceps skinfold thickness, mid arm circumference), dual energy x-ray absorptiometry (DEXA), and bioelectrical impedance analysis (BIA). Rectus abdominis muscle tissue and omental fat tissue will be harvested in the operating room, and the expression of signaling proteins involved in skeletal muscle protein synthesis will be quantified. The investigator will also quantify the expression of genes involved in lipolysis and lipid synthesis. The investigator anticipates that the expression of myostatin will be higher in the skeletal muscle and adipose tissue of cirrhotics as compared to controls. There will be a reduction in the expression of the signaling proteins that regulate skeletal muscle protein synthesis, as well as the expression of genes regulating lipogenesis. The increased expression of myostatin will also correlate with reduced anthropometric and DEXA measurements of lean body mass and fat mass.

Conditions

Cirrhosis

Study ID

NCT03121404

Start date

Nov 14, 2008

Status verified date

Jan, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age 18-70 years
  • Patients undergoing abdominal surgery (liver transplantation or other surgery)

Control

1. non liver transplant donor
2. Elective abdominal surgery (cholecystectomy, diverticulosis, acute gastrointestinal bleeding in the absence of exclusion criteria)

Exclusion Criteria:

  • Exclusion criteria (all subjects)
  • Average daily alcohol intake > 20 g in women and > 30 g in men
  • Diabetes or a fasting serum glucose > 100 mg/dL
  • Hyper- / hypo- thyroidism
  • Renal disease with serum creatinine > 1.4 mg/dL
  • Folate or vitamin B12 deficiency
  • Active intravenous drug use
  • History of bowel surgery or gastric bypass surgery
  • Medications/supplements that affect fat mass or protein mass (creatine, glucocorticoids)
  • Pregnancy
  • Chronic diseases that result in cachexia (renal, cardiac, pulmonary, hematologic, cancer)
  • Hepatocellular cancer

Exclusion criteria (controls)

  • Evidence of malnutrition as quantified by triceps skinfold thickness, mid arm muscle area and creatinine height index)

Study Design

Enrollment

40 participants

Anticipated

Interventions and Outcome Measures

Arms

Cirrhosis Patient

Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).

Healthy Controls

Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.

Interventions

Rectus abdominis muscle biopsy

Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.

Primary outcome measure

  • Determine the difference in myostatin expression between healthy control and cirrhosis patients [ Time Frame: 15 minute biopsy ]

Central Contacts and Locations

Central contacts

Annette Bellar, MSLA

216-636-5247bellara@ccf.org

Revathi Penumatsa

penumar@ccf.org

Locations

Cleveland Clinic Foundation

Recruiting

Cleveland, Ohio, United States, 44195

Contacts

Principal Investigator:

Srinivasan Dasarathy, MD

More Information

Sponsor

The Cleveland Clinic

Last update posted

Jan 9, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by The Cleveland Clinic on 2026-01-09.